Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.
In breast cancer, 2 molecular targets are well established (ER/PR and HER2), and therapies directed to these proteins have demonstrated to be clinically useful. Despite the presence of the ER and PR, only half of the patients will respond to endocrine therapy, and less than 35% of patients with ErbB2-overexpressing metastatic breast cancer will respond to trastuzumab as a single agent. To improve survival of metastatic breast cancer patients with ER/PR positive and HER2 positive is critical to elucidate the mechanism of resistance or sensitivity of these tumors for a better selection depending on biologic molecular alterations. Recently, several studies addressing this issue have been reported. Here, we will focus on a comprehensive review of the currently available data.